Ionis reports 95% fewer HAE attacks after two years. Can DAWNZERA defend its dosing advantage?
Ionis reports sustained DAWNZERA HAE attack reductions over two years. See what the data reveal about dosing, safety and commercial growth.
Pharma & Biotech